19 SIXES CORES PROSTATE BIOPSY. FOR WHOM IT IS STILL JUSTIFIED AS INITIAL DIAGNOSTIC TOOL FOR DETECTION OF THE PROSTATE CANCER?

2010 ◽  
Vol 9 (2) ◽  
pp. 40
Author(s):  
P. Milonas ◽  
A. Zabarskas ◽  
J. Masiliunas ◽  
M. Jievaltas
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Diagnostic Tool

scholarly journals The use of European Randomized study of Screening for Prostate Cancer calculator as a diagnostic tool for prostate biopsy indication

2019 ◽  
Vol 120 (05) ◽  
pp. 331-335
Author(s):  
J. Breza ◽  
F. Subin ◽  
M. Bernadic ◽  
M. Tomas ◽  
D. Pindak
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Diagnostic Tool ◽  
Randomized Study

530: Termining Risk for Prostate Cancer at Prostate Biopsy using Genetic Markers

2005 ◽  
Vol 173 (4S) ◽  
pp. 144-145
Author(s):  
Robert K. Nam ◽  
William Zhang ◽  
John Trachtenberg ◽  
Michael A.S. Jewett ◽  
Steven Narod
Keyword(s):  
Prostate Cancer ◽  
Genetic Markers ◽  
Prostate Biopsy

1497: Predictive Value of Proliferative Inflammatory Atrophy (PIA) for Prostate Cancer on Repeat Prostate Biopsy

2006 ◽  
Vol 175 (4S) ◽  
pp. 483-483
Author(s):  
Charlie Jung ◽  
Michael S. Cookson ◽  
Matthew J. Putzi ◽  
Sam S. Chang ◽  
Joseph A. Smith ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Predictive Value ◽  
Proliferative Inflammatory Atrophy

scholarly journals Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jaegeun Lee ◽  
Seung Woo Yang ◽  
Long Jin ◽  
Chung Lyul Lee ◽  
Ji Yong Lee ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Diagnosis ◽  
Prostate Biopsy ◽  
Peripheral Zone ◽  
Transitional Zone ◽  
Gray Zone ◽  
Prostate Cancer Diagnosis ◽  
Psa Density ◽  
Diagnosis Group ◽  
Predictive Rate

Abstract Background Serum prostate-specific antigen (PSA) is widely used in screening tests for prostate cancer. As the low specificity of PSA results in unnecessary and invasive prostate biopsies, we evaluated the clinical significance of various PSAs and PSA density (PSAD) related to peripheral zones in patients with gray zone PSA level (4–10 ng/mL). Methods A total of 1300 patients underwent transrectal ultrasonography-guided prostate biopsy from 2014 to 2019. Among them, 545 patients in the gray zone were divided into the prostate cancer diagnosis group and the non-prostate cancer diagnosis group, and PSA, relative extra transitional zone PSA (RETzPSA), estimated post holmium laser enucleation of the prostate PSA (EPHPSA), PSAD, peripheral zone PSA density (PZPSAD) and extra-transitional zone density (ETzD) were compared and analyzed using receiver-operating characteristics (ROC) analysis after 1:1 matching using propensity score. Results Area under the ROC curve values of PSA, EPHPSA, RETzPSA, PSA density, ETzD, and PZPSAD were 0.553 (95% CI: 0.495–0.610), 0.611 (95% CI: 0.554–0.666), 0.673 (95% CI: 0.617–0.725), 0.745 (95% CI: 0.693–0.793), 0.731 (95% CI: 0.677–0.780) and 0.677 (95% CI: 0.611–0.719), respectively. PSAD had 67.11% sensitivity, 71.71% specificity, and 70.34% positive predictive rate at 0.18 ng/mL/cc. ETzD had 69.08% sensitivity, 64.47% specificity, and 66.04% positive predictive rate at 0.04 ng/mL/cc. When the cut-off value of PSAD was increased to 0.18 ng/mL/cc, the best results were obtained with an odds ratio of 5.171 (95% CI: 3.171–8.432), followed by ETzD with 4.054 (95% CI: 2.513–6.540). Conclusions These results suggested that volume-adjusted parameters (ETzD and PSAD) might be more sensitive and accurate than various PSA in gray zone patients who required prostate biopsy to reduce unnecessary biopsy.

One-year experience of government-funded magnetic resonance imaging prior to prostate biopsy: A case for omitting biopsy in men with a negative magnetic resonance imaging

2021 ◽  
pp. 205141582110043
Author(s):  
Hanna J El-Khoury ◽  
Niranjan J Sathianathen ◽  
Yuxin Jiao ◽  
Reza Farzan ◽  
Dennis Gyomber ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Prostate Cancer ◽  
Magnetic Resonance ◽  
Prostate Biopsy ◽  
Multivariable Analysis ◽  
Transrectal Ultrasound ◽  
Resonance Imaging ◽  
Retrospective Case ◽  
Level Of Evidence ◽  
Clinically Significant

Objectives: This study aimed to characterise the accuracy of multiparametric magnetic resonance imaging (mpMRI) as an adjunct to prostate biopsy, and to assess the effect of the new Australian Medicare rebate on practice at a metropolitan public hospital. Patients and methods: We identified patients who underwent transrectal ultrasound (TRUS)-guided prostate biopsy at a single institution over a two-year period. Patients were placed into two groups, depending upon whether their consent was obtained before or after the introduction of the Australian Medicare rebate for mpMRI. We extracted data on mpMRI results and TRUS-guided biopsy histopathology. Descriptive statistics were used to demonstrate baseline patient characteristics as well as MRI and histopathology results. Results: A total of 252 patients were included for analysis, of whom 128 underwent biopsy following the introduction of the Medicare rebate for mpMRI. There was a significant association between Prostate Imaging Reporting and Data System v2 (PI-RADS) classification and the diagnosis of clinically significant prostate cancer ( p<0.01). Only one man with PI-RADS ⩽2 was found to have clinically significant prostate cancer. Four men with a PI-RADS 3 lesion were found to have clinically significant cancer. A PI-RADS 4 or 5 lesion was significantly associated with the diagnosis of clinically significant cancer on multivariable analysis. Conclusion: mpMRI is an important adjunct to biopsy in the diagnosis of clinically significant prostate cancer. Our findings support the safety of omitting/delaying prostate biopsy in men with negative mpMRI. Level of evidence: Level 3 retrospective case-control study.

scholarly journals 1924 PSA KINETICS DOES NOT PREDICT PROSTATE CANCER IN MEN SUBJECTED TO PROSTATE BIOPSY

2013 ◽  
Vol 189 (4S) ◽  
Author(s):  
Ignacio Iztueta Saavedra ◽  
Cristian Konstantinidis ◽  
Anna Celma ◽  
Fernando Ágreda ◽  
Jose Placer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Psa Kinetics

ARE PIN AND ASAP DIAGNOSED ON EXTENDED PROSTATE BIOPSY ASSOCIATED WITH THE SAME RISK OF PROSTATE CANCER ON REBIOPSIES?

2009 ◽  
Vol 181 (4S) ◽  
pp. 752-753
Author(s):  
Guillaume Ploussard ◽  
Gwendoline Plennevaux ◽  
Yves Allory ◽  
Laurent Salomon ◽  
Sandy Azoulay ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy
Sign in / Sign up

Export Citation Format

Share Document